

三葉草生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立的有限公司)

> (Stock Code: 2197) (股份代號: 2197)

NOTIFICATION LETTER 通知信函

May 21, 2025

Dear Non-registered holders(Note 1),

Clover Biopharmaceuticals, Ltd.* (the "Company")

- Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications

References are made to the announcements of the Company dated March 27, 2024 and June 20, 2024 titled "Arrangement of Electronic Dissemination of Corporate Communications", the Company is writing to remind you that the Company has adopted electronic dissemination of corporate communications ("Corporate Communications"), which means any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; (f) a reply slip; and (g) a proxy form.

Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at <u>www.cloverbiopharma.com</u> and the website of the Stock Exchange of Hong Kong Limited (the "Stock Exchange") at <u>www.hkexnews.hk</u> in place of printed copies (except for Actionable Corporate Communications (Note 2)).

The Company has not received your functional email address from the Intermediaries. As a non-registered shareholder, you should liaise with your bank(s), broker(s), custodian(s), nominee(s) or HKSCC Nominees Limited through which your Shares are held (collectively, the "Intermediaries") and provide your email address to your Intermediaries.

You may at any time choose to receive free-of-charge Corporate Communications either in printed form or to read the Company's Corporate Communications from the website of the Company or the Stock Exchange. If you want to receive Corporate Communications in printed form, please complete and return the Reply Form on the reverse side to the Company's Hong Kong share registrar (the "Share Registrar"), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong or send an email to clover.ecom@computershare.com.hk specifying your name, address and request to receive Corporate Communications in printed form. Please note that (i) selected instruction made previously to receive printed copies of Corporate Communications will be valid for one year from the receipt date of the shareholder's instruction; (ii) if a shareholder did not make election previously and fails to indicate this time to receive printed copies of Corporate Communications, only electronic future Corporate Communications will be available; and (iii) the election to receive a printed version of all future Corporate Communications will be valid for one year from the receipt date of the shareholder's instruction unless being revoked or superseded (whichever is earlier). Therefore, further request in writing will be required if a shareholder prefers to continue receiving printed copy of future Corporate Communications.

Should you have any queries relating to the above, please call the service hotline of the Share Registrar at (852) 2862 8688 during business hours (9:00 a.m. to 6:00 p.m. (Hong Kong time), Monday to Friday, excluding Hong Kong public holidays).

Yours faithfully, By order of the Board Clover Biopharmaceuticals, Ltd. Dr. Peng LIANG Chairman of the Board

Note 1: This letter is addressed to Non-registered holders ("Non-registered holder" means such person or company whose shares are held in The Central Clearing and Settlement System (CCASS) and who has notified the Company from time to time through Hong Kong Securities Clearing Company Limited to receive Corporate Communications). If you have sold or transferred your shares in the Company, please disregard this letter and the Reply Form on the reverse side.

Note 2: Actionable Corporate Communications refer to any corporate communications that seek instructions from issuer's securities holders on how they wish to exercise their rights or make an election as the issuer's securities holder.

各位非登記持有人(附註1):

三葉草生物製藥有限公司(「本公司」) - 以電子方式發佈公司通訊安排的提示信函

茲提述本公司日期為 2024 年 3 月 27 日及 2024 年 6 月 20 日有關「以電子方式發佈公司通訊之安排」之通知信函所述,本公司謹此提醒 閣下,公司已採用以電子方式發佈公司通訊(「公司通訊」)之安排,該公司通訊是指公司為向其任何證券持有人提供資訊或提醒其採取行動而發佈或將要發佈的任何文件,包括但不限於(a)董事報告、年度帳目以及審計報告副本以及(如適用)財務摘要報告; (b)中期報告及其中期報告摘要(如適用); (c)會議通知; (d)上市文件; (e)通函; (f)回執;和 (g)委任表格。

請注意,所有未來公司通訊的英文版和中文版將在公司網站 www.cloverbiopharma.com 和香港交易及結算所有限公司(「**聯交所**」)網站 www.hkexnews.hk 上提供,以代替印刷本(可供採取行動的公司通訊^(辦查2)除外)。

公司尚未有從中介公司收到 閣下就接收公司通訊提供電子郵件地址。作為非登記股東, 閣下應聯絡代閣下持有股份的銀行、經紀、託管商、代理人或香港中央結算(代理人)有限公司(統稱「中介公司」),並向 閣下的中介公司提供 閣下的電子郵件地址。

閣下可以隨時更改有關選擇,轉為收取印刷本或通過本公司的網站或聯交所網站瀏覽公司通訊。若 閣下希望收取公司通訊之印刷版,請填妥本函背頁之回執並交回公司的香港股份過戶登記處(「**股份過戶處**」)香港中央證券登記有限公司,地址為香港灣仔皇后大道東 183 號合和中心 17M 樓或發送電子郵件至 clover.ecom@computershare.com.hk,並註明 閣下的姓名、地址以及收取公司通訊印刷版的要求。請注意,(i)先前作出選擇收取公司通訊印刷本的指示將自收到股東指示當日起計一年內有效;(ii) 若股東未於先前作出選擇,且此次未指定收取公司通訊印刷本,則將僅提供未來公司通訊的電子版本;及(iii)選擇收取所有未來公司通訊之印刷本,將自收到股東指示當日起計一年內有效,除非被撤銷或取代(以較早者為準)。因此,如果股東希望繼續接收未來公司通訊的印刷本,則需要再提出書面要求。

如 閣下對上述事項有任何疑問,請於辦公時間內(星期一至星期五(香港公眾假期除外)上午9時正至下午6時正(香港時間))致電股份過戶處熱線(852)2862868查詢。

承董事會命 三葉草生物製藥有限公司 董事長 梁朋博士

2025年5月21日

附註1: 此函件乃向本公司之非登記持有人發出("非登記持有人"指股份存放於中央結算及交收系統的人士或公司,透過香港中央結算有限公司不時向本公司發出通知,希望收到公司通訊)。如果 閣下巳 經出售或轉讓所持有之本公司股份,則無需理會本函件及背面的回執。 附註2:可供採取行動的公司通訊指任何涉及要求發行人的證券持有人指示其擬如何行使其有關證券持有人的權利或作出選擇的公司通訊。

REPLY FORM		됐
------------	--	---

To: Computershare Hong Kong Investor Services Limited

> (The "Share Registrar") 17M Floor, Hopewell Centre,

183 Queen's Road East, Wan Chai, Hong Kong

致: 香港中央證券登記有限公司

(「股份猧戶處」)

香港灣仔皇后大道東 183 號

合和中心 17M 樓

REMINDER 提示

As a non-registered shareholder, you should liaise with your bank(s), broker(s), custodian(s), nominee(s) or HKSCC Nominees Limited through which your shares are held (collectively, the "Intermediaries") and provide your email address to your Intermediaries.

閣下持有股份的銀行、經紀、託管商、代理人或香港中央結算(代理人)有限公司(統稱「中介公 閣下應聯絡 作為非登記股東, 司」),並向 閣下的中介公司提供 閣下的電子郵件地址。

Request for Corporate Communications* in printed form / 要求收取公司通訊*印刷版 (Please mark "\sigma" in the below box if applicable) (如適用·請在以下方格內劃上「\square,」號)					
	any"):三葉草生物製藥有限公司	T. 3			
上市公司(「 公司 」)名稱:	Clover Biopharmaceuticals	, Ltd			
I/we would like to receive future Corporate Communications* in printed form. 本人/我們欲收取未來公司通訊 的印刷版。					
☐ Printed English version 英文	印刷本 Printed Chinese version 中文印刷本	Printed English and Chinese ve	rsions 中、英文印刷本		
Name(s) of Non-registered holder(s): 非登記股東姓名:		Signature(s): ^(Note 1) 簽名: ^(附註 1)			
	(Please use ENGLISH BLOCK LETTERS 請用英文正楷填寫)				
Contact number: 聯絡電話號碼:		Date: 日期:			

Notes:

This Reply Form is addressed to non-registered holder(s) ("Non-registered holder" means such person or company whose shares are held in The Central Clearing and Settlement System (CCASS) and who has notified the Company from time to time through Hong Kong Securities Clearing Company Limited that such person or company wishes to receive Corporate Communications*).

此回執乃向本公司之非登記股東(「非登記股東」指股份存放於中央結算及交收系統的人士或公司・已透過香港中央結算有限公司不時向本公司發出通知・表示欲收取公司通訊。) 發出。

- Please complete all your details clearly. 請 閣下清楚填妥所有資料。

- Any form with no box marked (Y), with no signature or otherwise incorrectly completed will be void. 如在本表格未有在方格内劃上「乂」號、或未有簽署、或在其他方面填寫不正確・則本表格將會作廢。
- For the avoidance of doubt, the Company does not accept any other instructions given on this Reply Form. 為免存疑·在本回執上的任何額外指示·公司將不予處理。
- Unless otherwise specified, Corporate Communications refer to any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to the annual report, interim report, notice of meeting, circular and proxy form. 除非另有註明·公司通訊乃指公司已發出或將予發出以供其任何證券的持有人參照或採取行動的任何文件·其中包括但不限於年報、中期報告、會議通告、通函及代表委任表格。

PERSONAL INFORMATION COLLECTION STATEMENT

- "Personal Data" in this statement has the same meaning as "personal data" in the Personal Data (Privacy) Ordinance, Chapter 486 of the Laws of Hong Kong ("PDPO"). 本聲明中所指的「個人資料」與香港法例第 486 章《個人資料(私隱)條例》(「《私隱條例》」)中「個人資料」的涵義相同。
 Your Personal Data provided in this Reply Form will be used in connection with the Company's electronic dissemination of Corporate Communications. Your supply of Personal Data to the Company is on a voluntary basis. In case of a failure to provide sufficient information, the Company may not be able to process your instructions and/or requests as stated in this Reply Form. 閣下於本回執所提供的個人資料將用於有關公司以電子方式發布公司通訊的事宜上。 閣下是自願向本公司提供個人資料。若 閣下未能提供足夠資料,本公司可能無法處理 閣下在 本回執上所述的指示及/或要求。
- (iii) Your Personal Data may be disclosed or transferred by the Company to its subsidiaries, the Share Registrar, and/or other companies or bodies for any of the stated purposes, or when it is required to do so by law and will be retained for such period as may be necessary for our verification and record purposes. 公司可就任何所說明的用途或在法例規定的情況下,將 閣下的個人資料披露或轉移給公司的附屬公司、股份過戶處、及/或其他公司或團體,並將在適當期間保留該等個人資料作 核實及紀錄用涂。
- You have the right to request access to and/or correction of your Personal Data in accordance with the provisions of the PDPO. Any such request for access to and/or correction of your Personal Data should be in writing, by mail to the Hong Kong Privacy Officer of the Share Registrar at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong or by email at PrivacyOfficer@computershare.com.hk. 閣下有權根據《私隱條例》的條文查閱及/或修改 閣下的個人資料。任何該等查閱及/或修改個人資料的要求均須以書面方式郵寄至股份過戶處(地址為香港灣仔皇后大道東 183 號

合和中心 17M 樓)向香港隱私主任提出,或發送電郵至 PrivacyOfficer@computershare.com.hk

Mailing Label 郵寄標籤

Computershare Hong Kong Investor Services Limited 香港中央證券登記有限公司 Freepost No. 簡便回郵號碼:37 Hong Kong 香港

Please cut the mailing label and stick it on an envelope to return this form to us. No postage is necessary if posted in Hong Kong.

> 當 閣下客同此同執時,請將郵客標籤煎貼於信封上。 如在本港投寄 · 閣下無需支付郵費或貼上郵票。